The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS).
 
Julia C. F. Quintanilha
Patents, Royalties, Other Intellectual Property - 16/932,002
 
Susan Michelle Geyer
Research Funding - Brisol-Myers-Squibb (Inst)
 
Jin Wang
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Amy Etheridge
No Relationships to Disclose
 
Stefanie Denning
No Relationships to Disclose
 
Alessandro Racioppi
No Relationships to Disclose
 
Kelli Hammond
Employment - Asklepios BioPharmaceutical (I)
 
Daniel Crona
No Relationships to Disclose
 
Carol Elaine Pena
Employment - Bayer; Merck
Stock and Other Ownership Interests - Bayer; Merck
Patents, Royalties, Other Intellectual Property - Patents from work at Bayer as a Bayer employee
Travel, Accommodations, Expenses - Bayer
 
Sawyer B. Jacobson
No Relationships to Disclose
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Federico Innocenti
Consulting or Advisory Role - Emerald Lake Safety; Symberix
Patents, Royalties, Other Intellectual Property - United States Patent: "Flavopiridol drug combinations and methods with reduced side effects", Ratain MJ, Innocenti F, Iyer L. Filed on April 12, 2001, serial number 09/835,082.; United States Patent: “Optimization of cancer treatment with irinotecan”, Ratain MJ, Innocenti F, Karabatsos P, Grimsley C, Di Rienzo A. Filed on February 12, 2003, serial number 60/446,942.; United States Provisional Application ”Methods of identifying risk of bevacizumab-induced proteinuria and hypertension”, Innocenti F, Quintanilha J, Lin D, Owzar K, Wang J. Filed on September 20, 2019, serial number 62/903,442.